Phase I/II Trial of the Safety and Efficacy of AE-941 (Neovastat®) in the Treatment of Non–Small-Cell Lung Cancer-Reference-Cited by-同舟云学术

Phase I/II Trial of the Safety and Efficacy of AE-941 (Neovastat®) in the Treatment of Non–Small-Cell Lung Cancer

Published:2003-01 Issue:4 Volume:4 Page:231-236
ISSN:1525-7304
Container-title:Clinical Lung Cancer
language:en
Short-container-title:Clinical Lung Cancer

Author:

Latreille Jean,Batist Gerald,Laberge Francis,Champagne Pierre,Croteau Daniel,Falardeau Pierre,Levinton Carey,Hariton Claude,Evans William K.,Dupont Eric

Publisher

Elsevier BV

Subject

Cancer Research,Pulmonary and Respiratory Medicine,Oncology

Reference24 articles.

1. Cancer Facts & Figures 2002,2002

2. Clinical practice guidelines for the treatment of unresected non-small-cell lung cancer;American Society of Clinical Oncology;J Clin Oncol,1997

3. Angiogenesis in cancer, vascular, rheumatoid and other disease;Folkman;Nat Med,1995

4. Tumor angiogenesis: therapeutic implications;Folkman;New Engl J Med,1971

5. Angiogenesis;Folkman;J Biol Chem,1992

Cited by 55 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Systematic evaluation of clinical efficacy of CYP1B1 gene polymorphism in EGFR mutant non-small cell lung cancer observed by medical image;Open Life Sciences;2023-01-01

2. The Role of Matrix Metalloproteinases in Endometriosis: A Potential Target;Biomolecules;2021-11-22

3. Application of marine natural products in drug research;Bioorganic & Medicinal Chemistry;2021-04

4. Immunomodulatory effects of shark cartilage: Stimulatory or anti-inflammatory;Process Biochemistry;2020-05

5. The past, present and future perspectives of matrix metalloproteinase inhibitors;Pharmacology & Therapeutics;2020-03